50 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
the research and development of new drugs in this field in the future. What kind of feedback has the Everest team received from the early access patient … 60.5 million and SEK 15.2 million for the year ended December 31, 2023 and 2022, respectively. Research and development expenses Research
6-K
EX-99.2
nrl4k4 isntorm9
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
6-K
3q6sg2gh
27 Dec 23
Current report (foreign)
4:05pm
6-K
EX-99.1
ozdot0dl5i4bi3j
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
e8m pvsdvukz
5 Oct 23
Current report (foreign)
4:05pm
6-K
EX-99.1
4syams jhssgt3
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
S-8
EX-4.1
rmqn0tgo28k84 b7
12 Jun 23
Registration of securities for employees
4:06pm
6-K
EX-99.1
ug5pk6c2m6ifohk9
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.1
gqcn7t 9jbsf26
28 Apr 23
Current report (foreign)
4:05pm
6-K
EX-99.1
txl8e4nawx
14 Nov 22
Current report (foreign)
5:25pm
6-K
EX-99.1
9c1dqlqp
19 Aug 22
Interim Report January 1ST – June 30TH 2022
7:55am
F-3
8mkhvxb1lz6
28 Jun 22
Shelf registration (foreign)
4:49pm